New DRUG May Lower SHBG In the Future

[Jpin22]

For those with either NAFLD/NASH or high lipids (trigylcerides, ldl, etc), a drug called mgl-3196 by Madrigal Pharm. just concluded its phase 2 trial and patients had an average of their SHBG increasing 80% from baseline with some over 100%. Drug also statistically significantly lowered trigylcerides, ldl, lp(a), and apo b.

 

[Ardoc2]

Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018